Case Report Open Access
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2023; 11(7): 1600-1606
Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1600
Rheumatic valvular heart disease treated with traditional Chinese medicine: A case report
Wei-Hang Chen, Yan Tan, Zhao-Heng Liu, School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China
Ya-Lei Wang, Xu Wang, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China
ORCID number: Wei-Hang Chen (0000-0002-1144-7372); Yan Tan (0000-0003-1587-8273); Ya-Lei Wang (0000-0002-8298-2401); Xu Wang (0000-0003-1155-3383); Zhao-Heng Liu (0000-0002-4729-8102).
Author contributions: Chen WH and Tan Y contributed equally to this work; Chen WH contributed to original draft writing and editing; Tan Y contributed to editing and data analysis; Wang YL and Wang X contributed to data collection; Liu ZH contributed to supervision; all authors have read and approved the final manuscript.
Supported by the National Natural Science Foundation of China Project, No. 81904049.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: All authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhao-Heng Liu, MD, School of Life Sciences, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 102488, China. zliu@bucm.edu.cn
Received: November 4, 2022
Peer-review started: November 4, 2022
First decision: January 5, 2023
Revised: January 19, 2023
Accepted: February 13, 2023
Article in press: February 13, 2023
Published online: March 6, 2023
Processing time: 118 Days and 3 Hours

Abstract
BACKGROUND

Rheumatic heart disease (RHD) is an autoimmune disease that leads to irreversible valve damage and heart failure. Surgery is an effective treatment; however, it is invasive and carries risks, restricting its broad application. Therefore, it is essential to find alternative nonsurgical treatments for RHD.

CASE SUMMARY

A 57-year-old woman was assessed with cardiac color Doppler ultrasound, left heart function tests, and tissue Doppler imaging evaluation at Zhongshan Hospital of Fudan University. The results showed mild mitral valve stenosis with mild to moderate mitral and aortic regurgitation, confirming a diagnosis of rheumatic valve disease. After her symptoms became severe, with frequent ventricular tachycardia and supraventricular tachycardia > 200 beats per minute, her physicians recommended surgery. During a 10-day preoperative waiting period, the patient asked to be treated with traditional Chinese medicine. After 1 week of this treatment, her symptoms improved significantly, including resolution of the ventricular tachycardia, and the surgery was postponed pending further follow-up. At 3 -month follow-up, color Doppler ultrasound showed mild mitral valve stenosis with mild mitral and aortic regurgitation. Therefore, it was determined that no surgical treatment was required.

CONCLUSION

Traditional Chinese medicine treatment effectively relieves symptoms of RHD, particularly mitral valve stenosis and mitral and aortic regurgitation.

Key Words: Rheumatic heart disease; Valvular damage; Mitral stenosis; Chinese formulas; Traditional Chinese medicine treatment; Case report

Core Tip: Rheumatic heart disease (RHD) is an autoimmune disease. This case report describes a 57-year-old woman with a 1-year history of RHD who presented with chest tightness, palpitations, and fatigue. She was successfully treated with the modified Ling Gui Zhu Gan decoction. We discuss how this prescription became an effective treatment for RHD.



INTRODUCTION

Rheumatic heart disease (RHD) is an autoimmune disease caused by group A streptococcal infection in the throat, lungs, and heart[1]. This disease can affect multiple organs and lead to irreversible valve damage and heart failure, with mitral stenosis being the most common. The predisposing cause of RHD is acute rheumatic fever. The most common symptoms of RHD are palpitations, shortness of breath, chest tightness, asthma, fatigue, and weakness[2,3]. This condition remains a significant global health burden, with high health care costs and significant technical expertise required for multidisciplinary approach to management[4]. Surgery is a relatively effective treatment for RHD. However, long-term postoperative medication significantly limits the quality of life for patients with RHD.

CASE PRESENTATION
Chief complaints

A 57-year-old woman was evaluated for palpitations, chest tightness, and weakness that began more than 1 year ago. Her symptoms had become increasingly severe, with frequent ventricular tachycardia and supraventricular tachycardia > 200 beats per minute.

History of present illness

The patient was evaluated by the internal medicine team on January 10, 2021. She described experiencing palpitations and chest tightness for the past 1 year. In addition, she reported poor sleep quality, chronic cold hands and feet, sore mouth, and dry throat. On physical examination, she was slightly obese and had a good pulse. Petechiae were observed on her tongue and her lips and tongue appeared dark red.

History of past illness

The patient has no history of past illness.

Personal and family history

The patient has no personal and family history.

Physical examination

The patient has no physical examination.

Laboratory examinations

The patient has no laboratory examinations.

Imaging examinations

Imaging examinations showed the following: aortic root internal diameter 31 mm; left atrial internal diameter 38 mm; left ventricular (LV) end-diastolic diameter 46 mm; LV end-systolic diameter 30 mm; interventricular septum thickness of 8 mm; LV posterior wall thickness 8 mm; and pulmonary artery systolic pressure 34 mm Hg, as shown in Table 1 (Before Treatment).

Table 1 M-mode and blood flow Doppler ultrasound measurement: Comparison of traditional Chinese medicine prescription before and after treatment.
NameMeasured value
Normal value (mm)

Before treatment
After treatment

Inner diameter of aortic root313520-37
Inner diameter of the left atrium384019-40
LV end-diastolic diameter464435-56
LV end-systolic diameter303123-35
Septal thickness886-11
LV posterior wall thickness886-11
Aortic regurgitation areaa3.9 cm22.4 cm2Mild to moderate < 8 cm²; Moderate 3-5 cm²; Mild < 3 cm²
LV ejection fractiona64%70%50%-70%

Her LV ejection fraction was 64%. Mitral flow mapping showed a stenotic waveform tissue Doppler imaging (TDI) and an S wave peaking at 10 cm/s. The mitral valve was thickened, and the leaflets were open and protuberant. The area of aortic regurgitation was approximately 3.9 cm2, according to two-dimensional tracings. The leaflet closing morphology was unremarkable, and color Doppler indicated mild to moderate mitral regurgitation.

FINAL DIAGNOSIS

The patient was diagnosed with mild to moderate RHD based on the color Doppler echocardiography, LV function tests, and TDI. From the approach of traditional Chinese medicine, the diagnosis of chest obstruction was made based on her main clinical symptoms, and the syndrome type was heart and kidney yang deficiency.

TREATMENT

Based on the patient’s symptoms, imaging results, and diagnosis, the medical team scheduled the patient for mitral valve repair surgery in 10 d. The patient requested that treatment be initiated immediately with traditional Chinese medicine during this preoperative waiting period.

For treatment with traditional Chinese medicine, we used a self-prepared formula containing Radix Astragali (10 g), Ramulus Cinnamomi (6 g), Rhizoma Atractylodis (15 g), Radix et Rhizoma Glycyrrhizae (9 g), Radix Saposhnikoviae (10 g), Radix Paeoniae Alba (10 g), Radix Paeoniae Rubra (10 g), Radix puerariae (10 g), Rhizoma Phragmitis (15 g), Radix Ophiopogonis (10 g), Flos Lonicerae Japonicae (10 g), Poria (10 g), Radix et Rhizoma Salviae Miltiorrhizae (10 g), Rhizoma Curcumae (10 g) and Pericarpium Citri Reticulatae (15 g). The main functions of this formula are diuresis and dehumidification, promoting blood circulation and removing blood stasis. To administer the daily dose, formula is boiled with water and taken 30 min after breakfast and dinner.

After 7 d of treatment, the patient was evaluated at follow-up on January 23, 2021. She reported relief of her symptoms and described feeling that her “heart became warm and moist.” The patient adhered to the traditional Chinese medicine treatment for another 21 d after this evaluation.

OUTCOME AND FOLLOW-UP

At 3 mo follow-up (April 12, 2021), the patient was examined at Fuwai Hospital of the Chinese Academy of Chinese Medical Sciences (Table 1, After Treatment). Compared with the previous results of the color Doppler ultrasound, the patient showed improvement in aortic regurgitation from moderate (3.9 cm2) to mild (2.4 cm2) and in the LV ejection fraction from 67% to 70%. The patient was followed weekly for 6 months after initiation of the traditional Chinese medicine treatment, and the ventricular tachycardia did not reappear. Her improvement of cardiac symptoms was attributed to the effects of the 20 administered herbs. At the final follow-up 1 mo later (May 11, 2021), the result was RHD with mild mitral stenosis and mild regurgitation and aortic regurgitation.

DISCUSSION

Rheumatic heart disease is a major global health problem, causing approximately 300000 deaths yearly[5]. This disease predominantly affects the heart valves, which may have inflammatory adhesions, calcinosis, and fibrosis. Each valve of the heart has a different probability for manifesting RHD. Mitral valve stenosis is the most often affected valve in RHD and is common among female patients. Patients with RHD usually have poor quality of life given the high rates of disability and mortality[6-8]. However, the exact pathogenesis of valve impairment remains unclear. It is believed that in the susceptible populations, specific strains of group A streptococci trigger the formation of autoantibodies in the host tissues, including the heart, through molecular mimicry, ultimately leading to valve damage[9].

As a noninvasive approach, Doppler echocardiography has become one of the primary methods for the clinical diagnosis of valvular pathology. This imaging study measures the size of the heart chamber and ventricular function. It also measures the pressure difference across the valve, the valve opening area, the pulmonary artery pressure, and other indicators. It is essential to distinguish RHD from other diseases, such as connective tissue disease, poststreptococcal infection, acute septic arthritis, rheumatoid arthritis, viral myocarditis, and infective endocarditis.

Surgery is often required to repair or replace the heart valves for patients with severely damaged valves. Percutaneous mitral balloon angioplasty has become a guiding principle for management of RHD, both nationally and internationally. It is recommended as the treatment for rheumatic mitral stenosis because of its low invasiveness, high safety, and short- and long-term efficacy[10,11]. However, expensive life-saving cardiac surgery is not available for all patients with RHD because only a few cardiac surgery facilities exist in low-income countries where RHD is endemic[12]. Previously, diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and anti-infectious agents were often administered in clinical practice, but the improvement of cardiac function was unsatisfactory.

In this case report, the patient, described the typical RHD symptoms, including palpitations, chest tightness, poor sleep, cold limbs over a long time, bitter mouth, and dry throat. Therefore, both before and after treatment, we administered the 36-Item Short Form Survey Instrument (SF-36, part of the Medical Outcomes Study) and the Visual Analog Scale (VAS) to evaluate the health status of patients. Compared with the SF-36 results before treatment with traditional Chinese medicine, the post-treatment results showed that the patient's health condition was improved, and the VAS results showed that the patient’s degree of chest tightness was reduced both during the day and night (Figure 1 and Table 2). These results show that the Chinese herbal formula can achieve excellent results. Our analysis of this effect is that, from the perspective of traditional Chinese medicine, RHD is mainly caused by exogenous pathogenic wind, cold, and dampness.

Figure 1
Figure 1 Comparison of the patient’s Visual Analog Scale results before and after treatment. Results are shown for day and night for 0-10 min on a 0-100 mm scale, for which a score of 0 scale indicates no symptoms, and 100 indicates the most severe degree of chest tightness. The √ mark represents the mark that the patient makes on the corresponding scale according to their experience of the symptom.
Table 2 Comparison of scores of SF-36 health survey before and after treatment.
Item
Before treatment (Full score 100 points)a
After treatment (Full score 100 points)a
Physical functioning4590
Role-physical100100
Bodily pain80100
General health2542
Vitality4080
Social functioning62.587.5
Role-emotional0100
Mental health4076
Reported health transition075

After treatment with Chinese herbal medicine, the patient’s area of aortic regurgitation decreased significantly, and the ejection fraction increased. Our prescription formula uses Ramulus Cinnamomi to warm the yang qi and dispel the cold wind, and Poria is used to dispel dampness. These two agents can be used in combination for warming and tonifying yang so as to strengthen the heart and promote blood circulation; in addition, they function as a diuretic and dispel the wind, cold, and dampness so the symptoms can be relieved. Chemical medicine, including diuretics and vasodilators, are used to reduce the high cardiac load Thua, these two monarch drugs of traditional Chinese medicine may have the same functions as the chemical drugs.

The other herbs in this formula, such as Radix Astragali and Rhizoma Atractylodis, are used to replenish qi, strengthen the surface, spleens and sooth the heart. Radix Paeoniae Alba nourishes blood and regulates menstruation. Radix Paeoniae Rubra combined with Radix et Rhizoma Salviae Miltiorrhizae has the effect of activating blood circulation. Radix et Rhizoma Glycyrrhizae harmonizes all these herbs because it can open pathways of resistance and eliminate paralysis. Modern pharmacologic studies have shown that astragalus also enhances immunity, diuresis, antistress, and anti-inflammatory effects[13]. In addition, astragalus can enhance myocardial contractility, expand coronary arteries, and improve myocardial blood supply. glucosides of paeony improves hypoxia, promotes antioxidation, and relieves fatigue. Atractylodes macrocephala and atractylodes rhizome have diuretic and vasodilatory effects[14-16]. Poria can enhance immunity. Ramulus cinnamomi has diuretic, cardiotonic, vasodilator, analgesic, and anticonvulsant effects. Rhizoma Curcumae can inhibit platelet aggregation, improve microcirculation, promote arterial blood flow, and regulate immune function, with antibacterial, anti-inflammatory, and analgesic effects[17,18]. Radix et Rhizoma Salviae Miltiorrhizae contains tanshinone and other active ingredients that improve the symptoms related to heart disease; it also improves sleep disorders[19]. The flavonoids and puerarin in Radix Puerariae Lobatae reduce the peripheral resistance of the heart, nourish the heart muscle, and expand blood vessels[20,21]. Calcium isocitrate in Rhizoma Phragmitis can strengthen the heart and promote blood circulation[22]. The alcohol in Pericarpium Citri Reticulatae increases the elasticity of blood vessels[23]. At present, more than 10 types of RHD syndrome are known in traditional Chinese medicine, as follows: (1) Heart-blood stasis type; (2) Qi and yin deficiency type; (3) Blood vessel stasis type; (4) Qi and blood deficiency type; (5) Blood stasis type; (6) Qi and blood deficiency type; (7) Heart and kidney yang deficiency type; and (8) Yang and yin deficiency type[24]. The intervention measures include traditional Chinese medicine formulas, Chinese patent medicine, acupuncture, and massage. Patients can be treated with traditional Chinese medicine alone or with traditional Chinese medicine combined with modern treatment. Currently, specific therapeutic indicators are lacking for the use of traditional Chinese medicine to treat RHD. Based on this patient’s experience and the discussion, this case report is expected to contribute to providing a higher quality schema for the use of traditional Chinese medicine to diagnose and treat RHD.

CONCLUSION

The case reported here suggests that herbal formula can effectively relieve the symptoms of RHD. These findings provide new insights into the treatment of RHD and a basis for further research to determine the underlying mechanisms.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Medicine, research and experimental

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Khurram H, Pakistan; Ong H, Malaysia S-Editor: Wang LL L-Editor: A P-Editor: Wang LL

References
1.  Muhamed B, Parks T, Sliwa K. Genetics of rheumatic fever and rheumatic heart disease. Nat Rev Cardiol. 2020;17:145-154.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 32]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
2.  Sampath Kumar A. Surgical options in rheumatic heart disease: an Indian surgeon's perspective. Asian Cardiovasc Thorac Ann. 2020;28:371-373.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
3.  Hollenberg SM. Valvular Heart Disease in Adults: Etiologies, Classification, and Diagnosis. FP Essent. 2017;457:11-16.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Remenyi B, ElGuindy A, Smith SC Jr, Yacoub M, Holmes DR Jr. Valvular aspects of rheumatic heart disease. Lancet. 2016;387:1335-1346.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 97]  [Article Influence: 12.1]  [Reference Citation Analysis (0)]
5.  Xian S, Chen A, Wu X, Lu C, Wu Y, Huang F, Zeng Z. Activation of activin/Smad2 and 3 signaling pathway and the potential involvement of endothelialmesenchymal transition in the valvular damage due to rheumatic heart disease. Mol Med Rep. 2021;23.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 5]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
6.  Tormin JPAS, Nascimento BR, Sable CA, da Silva JLP, Brandao-de-Resende C, Rocha LPC, Pinto CHR, Neves EGA, Macedo FVB, Fraga CL, Oliveira KKB, Diamantino AC, Ribeiro ALP, Beaton AZ, Nunes MCP, Dutra WO; PROVAR (Programa de RastreamentO da VAlvopatia Reumática) investigators. Cytokine gene functional polymorphisms and phenotypic expression as predictors of evolution from latent to clinical rheumatic heart disease. Cytokine. 2021;138:155370.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 10]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
7.  Cantinotti M, Emdin M, Clerico A. B-type natriuretic peptide assay for complex congenital heart diseases: clinical relevance versus methodological issues. J Am Coll Cardiol. 2013;61:2022-2023.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
8.  Passeri JJ, Dal-Bianco JP. Percutaneous balloon mitral valvuloplasty: Echocardiographic eligibility and procedural guidance. Interv Cardiol Clin. 2018;7:405-413.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
9.  Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet. 2005;366:155-168.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 397]  [Cited by in F6Publishing: 352]  [Article Influence: 18.5]  [Reference Citation Analysis (0)]
10.  Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-2791.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4127]  [Cited by in F6Publishing: 4272]  [Article Influence: 610.3]  [Reference Citation Analysis (0)]
11.  Agus HZ, Kahraman S, Uygur B, Guler A, Demirci G, Kalkan AK, Erturk M, Yildiz M. Immediate And Long Term Effects Of Percutaneous Mitral Balloon Valvuloplasty On Atrial Conduction Velocities In Patients With Mitral Stenosis. J Atr Fibrillation. 2019;11:2124.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
12.  Pezzella AT. Global aspects of cardiothoracic surgery with focus on developing countries. Asian Cardiovasc Thorac Ann. 2010;18:299-310.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 35]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
13.  Yang QY, Chen KJ, Lu S, Sun HR. Research progress on mechanism of action of Radix Astragalus in the treatment of heart failure. Chin J Integr Med. 2012;18:235-240.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 15]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
14.  Zhang L, Wei W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther. 2020;207:107452.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 128]  [Cited by in F6Publishing: 303]  [Article Influence: 60.6]  [Reference Citation Analysis (0)]
15.  Chen Y, Yang W, Guo L, Wu X, Zhang T, Liu J, Zhang J. Atractylodes lactone compounds inhibit platelet activation. Platelets. 2017;28:194-202.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 17]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
16.  Ruqiao L, Yueli C, Xuelan Z, Huifen L, Xin Z, Danjie Z, Le S, Yanxue Z. Rhizoma Atractylodis macrocephalae: a review of photochemistry, pharmacokinetics and pharmacology. Pharmazie. 2020;75:42-55.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 6]  [Reference Citation Analysis (0)]
17.  Li X, He Y, Zeng P, Liu Y, Zhang M, Hao C, Wang H, Lv Z, Zhang L. Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China. J Cell Mol Med. 2019;23:4-20.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 58]  [Cited by in F6Publishing: 96]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
18.  Guo Q, Mao X, Zhang Y, Meng S, Xi Y, Ding Y, Zhang X, Dai Y, Liu X, Wang C, Li Y, Lin N. Correction to: Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance. J Transl Med. 2020;18:372.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
19.  Zhang X, Wang Q, Wang X, Chen X, Shao M, Zhang Q, Guo D, Wu Y, Li C, Wang W, Wang Y. Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway. Biomed Pharmacother. 2019;112:108599.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 47]  [Article Influence: 9.4]  [Reference Citation Analysis (0)]
20.  Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69:273-278.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 311]  [Cited by in F6Publishing: 383]  [Article Influence: 27.4]  [Reference Citation Analysis (0)]
21.  Zhang L. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv. 2019;26:860-869.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 73]  [Cited by in F6Publishing: 85]  [Article Influence: 17.0]  [Reference Citation Analysis (0)]
22.  Park SJ, Kim YW, Park MK, Byun SH, Kim SC, Lee JR. Anti-inflammatory Steroid from Phragmitis rhizoma Modulates LPS-Mediated Signaling Through Inhibition of NF-κB Pathway. Inflammation. 2016;39:727-734.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 14]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
23.  Malik A, Najda A, Bains A, Nurzyńska-Wierdak R, Chawla P. Characterization of Citrusnobilis Peel Methanolic Extract for Antioxidant, Antimicrobial, and Anti-Inflammatory Activity. Molecules. 2021;26.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 11]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
24.  Sheng XD, Chao C, Ting Z, Hu HY, Ji ZC, Niu BH, Zhang MY, Zhang D, Guo LP, Wang H, Zhang JH. [Current situation analysis of evaluation indexes of randomized controlled trials of traditional Chinese medicine in the treatment of rheumatic heart disease]. Zhongguo Zhongyao Zazhi. 2022;47:244.  [PubMed]  [DOI]  [Cited in This Article: ]